Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy? Reply

被引：0

作者：

Mayer, Ingrid A. ^{[1
]}

Zhao, Fengmin ^{[2
]}

Arteaga, Carlos L. ^{[3
]}

Symmans, William F. ^{[4
]}

Park, Ben H. ^{[1
]}

Burnette, Brian L. ^{[5
]}

Tevaarwerk, Amye J. ^{[6
]}

Garcia, Sofia F. ^{[7
]}

Smith, Karen L. ^{[8
]}

Makower, Della F. ^{[9
]}

Block, Margaret ^{[10
]}

Morley, Kimberly A. ^{[11
]}

Jani, Chirag R. ^{[12
]}

Mescher, Craig ^{[13
]}

Dewani, Shabana J. ^{[14
]}

Tawfik, Bernard ^{[15
]}

Flaum, Lisa E. ^{[7
]}

Mayer, Erica L. ^{[16
]}

Sikov, William M. ^{[17
]}

Rodler, Eve T. ^{[18
]}

Wagner, Lynne I. ^{[19
]}

DeMichele, Angela M. ^{[20
]}

Sparano, Joseph A. ^{[9
]}

Wolff, Antonio C. ^{[8
]}

Miller, Kathy D. ^{[21
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA

[2] Dana Farber Canc Inst, ECOG ACRIN Biostat Ctr, Boston, MA 02115 USA

[3] UT Southwestern Simmons Canc Ctr, Dallas, TX USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Canc Res Wisconsin & Northern Michigan CROWN NCOR, Green Bay, WI USA

[6] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA

[7] Northwestern Univ, Evanston, IL USA

[8] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA

[9] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA

[10] Alegent Hlth Bergan Mercy Med Ctr, Omaha, NE USA

[11] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA

[12] Phoebe Putney Mem Hosp, Albany, GA USA

[13] Metro Minnesota Community Oncol Res Consortium, St Louis Pk, MN USA

[14] Columbus Oncol & Hematol Associates Inc, Columbus, OH USA

[15] Univ New Mexico Canc Ctr, Albuquerque, NM USA

[16] Dana Farber Canc Inst, Boston, MA 02115 USA

[17] Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA

[18] Univ Calif Davis, Davis, CA 95616 USA

[19] Wake Forest Univ Hlth Sci, Winston Salem, NC USA

[20] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[21] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Indianapolis, IN 46204 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 31期

基金：

美国国家卫生研究院;

关键词：

CAPECITABINE;

D O I：

10.1200/JCO.21.01905

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3522 / +

页数：3

共 50 条

[1] Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?
Shimanuki, Yumiko
Shimomura, Akihiko
Yoshimura, Kenichi
Terakado, Hiroyuki
Shimizu, Chikako
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3521 - +
[2] Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
Li, Zhijun
Han, Yiqun
Wang, Jiayu
Xu, Binghe
JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (02):
[3] Transcriptomic changes in invasive residual cancer after neoadjuvant chemotherapy in patients with triple-negative breast cancer
Orozco, Javier
Manughian-Peter, Ayla
Gago, Francisco
Chang, Grace
Grumley, Janie
Marzese, Diego
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 23 - 24
[4] Residual cancer burden and neoangiogenesis after neoadjuvant chemotherapy in triple-negative breast cancer
Miyashita, M.
Sasano, H.
Tamaki, K.
Hirakawa, H.
Ishida, T.
Ohuchi, N.
BREAST, 2017, 32 : S100 - S101
[5] Prognostic Impact of Residual Disease After Neoadjuvant Chemotherapy in 648 Patients with Triple-negative Breast Cancer
Kern, Peter
Von Minckwitz, Gunter
Puetter, Carolin
Pavlidou, Sofia
Flach, Annika
Kimmig, Rainer
Rezai, Mahdi
ANTICANCER RESEARCH, 2015, 35 (10) : 5479 - 5484
[6] Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Shimoi, Tatsunori
Noguchi, Emi
Sudo, Kazuki
Chua, Yu Jo
Yonemori, Kan
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) : 3519 - +
[7] An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
Blaye, C.
Darbo, E.
Debled, M.
Brouste, V
Velasco, V.
Pinard, C.
Larmonier, N.
Pellegrin, I
Tarricone, A.
Arnedos, M.
Commeny, J.
Bonnefoi, H.
Larmonier, C.
MacGrogan, G.
ESMO OPEN, 2022, 7 (04)
[8] An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
Blaye, C.
Darbo, E.
Debled, M.
Brouste, V.
Velasco, V.
Pinard, C.
Pellegrin, I.
Tarricone, A.
Arnedos, M.
Commeny, J.
Bonnefoi, H.
Larmonier, C.
Macgrogan, G.
ANNALS OF ONCOLOGY, 2022, 33 : S127 - S127
[9] Pathologic and immunohistochemical prognostic markers in residual triple-negative breast cancer after neoadjuvant chemotherapy
Ilie, Silvia Mihaela
Briot, Nathalie
Constatin, Guillaume
Ilie, Alis
Beltjens, Francoise
Ladoire, Sylvain
Desmoulins, Isabelle
Hennequin, Audrey
Bertaut, Aurelie
Coutant, Charles
Causeret, Sylvain
Ghozali, Niama
Coudert, Bruno
Arnould, Laurent
FRONTIERS IN ONCOLOGY, 2024, 13
[10] Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
Sohn, J.
Do, K. A.
Liu, S.
Chen, H.
Mills, G. B.
Hortobagyi, G. N.
Meric-Bernstam, F.
Gonzalez-Angulo, A. M.
ANNALS OF ONCOLOGY, 2013, 24 (10) : 2522 - 2526

← 1 2 3 4 5 →